An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Tezspire

Chemical Nametezepelumab-ekko
Dosage FormInjection (subcutaneous; 210 mg/1.91 mL (110 mg/mL))
Drug ClassMonoclonal antibodies
SystemRespiratory
CompanyAmgen
Approval Year2021

Indication

  • For the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma
Last updated on 3/15/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tezspire (tezepelumab-ekko) Prescribing Information.2021Amgen Inc., Thousand Oaks, CA
Document TitleYearSource
Tezepelumab for severe asthma. 2021ICER
Document TitleYearSource
The impact of monoclonal antibodies on airway smooth muscle contractility in asthma: a systematic review. 2021Biomedicines
Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.2019Respiratory Research